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1. Introduction 
Lymphatic filarial nematode parasites, mainly Wuchereria bancrofti and Brugia malayi, are 
causing agents of lymphatic filariasis in humans, which can be effectively treated with 
antifilarial drugs including diethylcarbamazine (DEC) and ivermectin. Albendazole, an 
effective benzimidazole compound, acts as a board-spectrum anthelminthic drug, and when 
combined with either one of antifilarial drugs, it exerts synergistic effects on reduction of 
peripheral microfilaremia in lymphatic filariasis cases. However, the varying parasite 
infection levels in those treated with DEC or ivermectin alone or in combination with 
albendazole are due to differences in drug responses. The additional clearance of infection 
with albendazole relative to what is observed with DEC or ivermectin alone suggests that 
albendazole has different parasite target(s). The homologous -tubulin gene of human and 
veterinary filariids that β-tubulin homologs have conserved domains structurally related 
to other orthologs among the nematodes, cestodes, trematodes and vertebrate hosts, is 
responsible for benzimidazole susceptibility. The genetic inheritance of resistance in 
nematode parasites can undergo under selection of benzimidazole compounds in a way 
that albendazole resistance mechanism involves one of two single amino acid 
substitutions from phenylalanine to tyrosine in parasite β-tubulin at position 167 or 200.  
This genetically-stable marker has shown promise for molecular diagnosis and 
monitoring of W. bancrofti infections that carry responsible genotypes associated with 
benzimidazole susceptibility or resistance. In particular, this approach can augment the 
surveillance and monitoring of mass treatment impacts on the parasite populations in 
target areas where long-running elimination programs for lymphatic filariasis are 
implemented at a large-scale by using a regionally-adopted combination therapy with 
antifilarial drugs, recommended by the World Health Organization.  
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2. Lymphatic filariasis towards elimination 
2.1 Factors that favor elimination 
Lymphatic filariasis (LF) is a mosquito-borne parasitic disease caused by three main species 
of thread-like filarial nematode parasites belonging to the superfamily Filarioidea, which are 
Wuchereria bancrofti and Brugia malayi, and lesser extent by Brugia timori. These endoparasitic 
nematode lifestyles have a highly conservative life-cycle development sequence in which 
they develop their metamorphosis in both human and mosquito (Fig. 1). The adult worms 
that cause clinical manifestations of the disease are dioecious. Male and female worms have 
separate reproductive system in their pseudocoelomatic body cavity and they live in the  
 
 
Fig. 1. A development sequence of filarial nematode parasite in human and mosquito (A-D). 
After the induction of L3 infection in susceptible human host, the mature filarial female 
worm (A) that possesses fecundicity and fertilization can produce microfilariae (Mf). These 
offsprings develop from fertilized eggs (B) in the uterus of female worm. They are ingested 
during the bite of mosquito vector, and consequently, a 5-stage molting progression (B) 
initially starts after exsheatment of the Mf in mosquito’s midgut (C). In this regard, the 
probable mechanisms involve: (a) proposed anterior of line of weakness, (b) internal 
digestion of the sheath, and (c) exsheatment of anterior end. Third stage larvae (L3) possess 
post-infective stage development in mosquito thoracic muscle and then migrate to the 
proboscis. They are transmitted by infective mosquito during a blood meal, and that they 
become the L4 (or L5) and mature adult worms in the lymphatic system in human. 
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human lymphatic system, i.e., lymphatic vessels, with 5-15 years of life expectancy (Table 1). 
Only when its fecundic lifespan is capable of mating does the lymphatic-dwelling female 
worm produce advanced stage of sheathed larvae called “microfilariae”. These short-living 
offsprings then penetrate the blood circulation. For a complete life cycle, the microfilariae 
are ingested by susceptible female mosquito during a blood meal in which they can develop 
further into larval stages L1-L2 to infective L3 stage. Transmission occurs when the infected 
mosquito transmits this L3 stage to susceptible persons during other blood meals. The 
naturally acquired transmission is associated with both intrinsic and extrinsic factors that 
can regulate the parasitic worm burdens in an endemic population (Fig. 2).  
 
 
Fig. 2. An explanatory model of human-parasite-vector interactions and favorable factors 
that influence its adaptation in hosts. The lymphatic filarial infections in humans depend on 
extrinsic factors of incoming L3 inocula and host recognition and location, and a proportion 
of adult worms with fecundicity and mating probability. Transmission is influenced by 
host-vector combination (host location and recognition of mosquito feeding habits), 
microfilarial loads in blood with timing of microfilariae release, and vectoral capacity 
(longevity and low refractoriness). Long lifespan of the mosquito and timing of L3 release 
are favorable factors of transmission. 
As such, understanding of how these filarial nematode parasites can be removed from the 
human hemisphere is to understand basically the biology of their life cycle. How do the 
parasite taxa succeed their complete life cycle in the certain conditions under which they 
evoke host exploitation strategies? The biology of the parasitic symbionts can disclosure the 
parasite diversity and fitness shaped by hosts and environmental constraints that the 
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parasites can evolve the adaptation, i.e., the ability to control the physiology and behavior of 
their host for their own benefit. It has been known so far their distribution among hosts and 
strategies of host exploitation are restricted in number of host species. The W. bancrofti, 
which is highly host-specific parasite, is sessile to human while other zoonotic Brugia taxa 
exploit other non-human reservoir hosts. This host-specificity variation does not account for 
the origin of the parasitism as they succeed their parasitism and share common transmission 
pattern and complex life cycle in vertebrate hosts and arthropods. The geographical 
variation, on the other hand, can be restrained by selective pressures from the hosts, or the 
physio-chemical environments such as therapeutic agents and insecticides, or due to 
phylogenetic constraints. Such this selection can be explained by the experimental 
infections, mainly using Brugia species in rodents (e.g., jirds, hamsters, rats and mice), dogs, 
ferrets, cats and monkeys. All of which were proposed not just for understanding vertebrate 
immunology, pathology and chemotherapy, but also for exploring the interactions of the 
parasite and host. Among these host-parasite systems, B. pahangi that infects naturally cats 
in the Southeast Asia is experimentally appropriate for studies of infection and disease 
dynamics (Table 1).  
 
Parameter Cat Human 
Parasite Brugia pahangi Wuchereria bancrofti 
B. malayi, B. timori 
Longevity (years) 7-8 5-15 
Mature female worm length (cm) 3-7 5-10 
Location of : 
   Adult 
   Microfilariae  
Vector 
 
Lymphatics 
Blood  
Mosquito 
 
Lymphatics 
Blood  
Mosquito 
Typical infection/disease sequlaea Infection –  
Loss of infection –  
Pathology 
Infection –  
Loss of infection –  
Pathology 
aFor both host-parasite systems, infection patterns encapsulate a spectrum ranging from asymptomatic 
persistent microfilaremia to symptomatic amicrofilaremia or complete refractoriness to infection. 
Adapted from Grenfell et al (1991). 
Table 1. Correlation between feline and human lymphatic filariasis 
Because of their conservation of complex life-cycle development between feline and human 
lymphatic filarial parasites, it induces the infection and clinical sequelae in susceptible cats, 
and hence, resembles that of Brugia and Wuchereria in humans. However, the parasite does 
not always succeed their population diversity by increasing its fitness in the hosts (Fig. 2). 
Its population dynamic is primarily influenced by naturally acquired immunity (i.e., a type 
of concomitant immunity), which plays a significant role in host selection pressure to restrict 
a parasitic worm burden (Bundy et al, 1991; Grenfell et al, 1991; Mitchell, 1991; Grenfell and 
Micheal, 1992). This immunity against incoming L3 cannot remove them from the infection 
in humans but restrict a number of L3 by a production of concomitant immunity. Variability 
of adult worm burden results in a proportion of microfilaremic and amicrofilaremic persons 
in the population. The circulating microfilariae have short life cycle in human blood 
circulation; a proportion of the microfilariae can be removed by anti-microfilarial antibody 
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(Simonsen et al, 1996; 2008; Ravindran et al, 2003). They develop two molts (L1 and L2) and 
induce the infection in susceptible mosquito vectors while the infected mosquitoes can 
regulate melanization involved in innate immune defense and wound healing to the 
penetration of filarial nematodes (Zou et al, 2010; Castillo et al, 2011). In blood-engorged 
mosquitoes that harbor high microfilarial density, they can induce death due to the vector 
intolerance against development of juvenile forms, and consequently, this leads to loss of 
L3. Furthermore, release of the L3 does not always permit a passage at an equal number 
during other blood meal taken by the infective mosquito due to the vector tolerance. Thus, 
they are naturally killed by host immune, vector barrier, and physical environment; these 
contributing factors can favor the LF elimination in humans. 
As was, LF becomes one of six potentially eradicable diseases of which the criteria for 
assessing their eradicability (CDC, 1993) are based not only on the scientific feasibility of 
understanding the biological information mentioned earlier and practical use of the public 
health interventions and other methods to be applied or used in existing national control 
program, but also on the political will or popular support of executing the implementation 
of LF control strategies. First, the scientific feasibility depends basically on the disease 
vulnerability. Unlike the W. bancrofti that exists only in humans, the B. malayi spends an 
enzoonotic life-cycle in which the parasite is transmitted by the potent mosquito and thrive 
in domestic cats as non-human reservoir, and a per se epizoonotic cycle in which the parasite 
is transmitted and thrive through which the mosquito vector takes blood meal from infected 
cats, and subsequently, transmit the infective stage to humans during other blood meal. 
Controversially, the humans carrying B. malayi infection can serve as a source for the 
infection to permit a passage to the animal reservoir through bites of the mosquito vector. 
Nonetheless, both diseases do not always ease their spread into the population as a result of 
the naturally-induced immunity and duration of microfilarial production in susceptible 
individuals or communities (Maizels and Lawrence, 1991; Ottesen, 1992) (Fig. 2). More 
important, the infections can be both easily diagnosed using advanced tools and effectively 
treated with the antifilarial drugs that are safe, inexpensive and easily deployed. The 
feasibility of elimination has been shown that the operation of the pragmatic diagnostic 
methods or interventions is demonstrable at a large scale in the target populations. Last, 
the political will/popular support is pivotal for the program manager to capture 
information required to analyze situations of the perceived burden of LF that is figured 
out by a large number of suffering and disabled persons worldwide (WHO, 2002; 2008; 
2010): the details are available at the websites of the Global Program to Eliminate 
Lymphatic Filariasis (GPELF) (http://www.who.int/lymphatic_filariasis/disease/en/) 
and Global Alliance to Eliminate Lymphatic Filariasis (http://www.filariasis.org). Also, 
the National Program to Eliminate Lymphatic Filariasis (PELF) by which the resource 
mobilization and funding structure are administered must be allied, by adopting the 
GPELF’s strategies, to practical considerations of interventions, methods, logistic supplies 
(medical and field-work), delivery processes, expenditures (unit costs and cost-
effectiveness), integration of control activities into existing health systems services (or 
other health development programs), socio-economic impacts on gaining health benefits, 
community awareness and acceptance, and ecological disturbances to target disease, non-
target disease and the environment. For the resource-limited countries as allied nations, a 
national budget plan that notifies outsources and fund raising needs the subsidy of the 
internationally collaborative program.  
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2.2 Mass chemotherapy as elimination strategy 
Ideally, the success of controlling the disease depends definitely on the objectives and 
ultimate goals of disease control spectrum (CDC, 1993); with this regard, the rational 
management of LF elimination differs with control (Table 2). As recommended by the World 
Health Organization (WHO), two pillars of global elimination strategies emphasize 
interruption of transmission and elimination of the infection in humans, and the other large-
scale morbidity control to prevent disease and disability (WHO, 1999a; 2002; 2008; 2010). 
Principle outcomes of the GPELF reduce numbers of microfilaremic persons and disease 
cases as preventing new infection introduced among the population at risk of, or affected 
with, the infection. To meet this criteria, the GPELF proposes a mainstay of elimination 
strategy effectively available for mass drug administration (MDA) in target population; a 
combined treatment with diethylcarbamzine citrate (DEC) 6 mg/kg plus 400 mg 
albendazole (in W. bancrofti transmssion areas where Onchocerca volvulus is not coendemic), 
or with 200 g ivermectin plus 400 mg albendazole (in W. bancrofti transmssion areas where 
O. volvulus is coendemic) (Ottesen et al, 1997; 1999; Ottesen, 2000; WHO, 1999a; 2000; 2001; 
2002). An annual MDA with coverage of 60-80% for 4-5 years is considered to be effective 
enough to interrupt transmission in control areas in the absence of vector control (Gyapong 
et al, 2005). Also, new options for mass treatment of at risk population are effectively 
available: DEC-fortified salt for 1 year; and a combination of single annual dose of 
albendazole plus DEC, followed by DEC-fortified salt (Weaver et al, 2011). The ample 
supply and distribution of DEC-fortified salt can be administered in some countries. 
2.3 Surveillance and monitoring systems 
As for presenting dynamics of the infection and disease in nature (Grenfell et al, 1991; 
Srividya et al, 1991; Ottesen, 1992; Meyrowitsch et al, 1995), the parasites cause a wide 
spectrum of clinical manifestations in the affected population that are characterized by 
asymptomatic microfilaremia, acute lymphatic inflammation and chronic lymphatic 
pathology (WHO, 1992a; 1992b; 1994). Susceptible persons develop clinically LF as a result 
of prolonged exposure to multiple infective bites of potent mosquitoes from several months 
to years. On the other hand, the people living for at least 6 months are at the greatest risk for 
the infection. The chronic filariasis cases represent a tip of the iceberg, as microfilaremic 
carriers are the reservoir of the infection to others. The prevalence and intensity of the 
infection in humans depends mainly upon a number of microfilaremic persons and a 
geometric mean of microfilarial loads in the affected population. These proximate measures 
are indicative of the degrees of endemicity.  The prevalence and geographical distribution of 
the disease are important not just for determination of its potential transmission in 
mosquito, but also for diagnosis and surveillance in different endemic settings. Therefore, 
the recognition of what is the filarial origin of the disease and where the affected individuals 
or communities are is fundamental for public health importance to identify the solution and 
control rationale. Diagnostic approaches that emphasize the detection and specific 
identification of microfilaremic infection in the individual by using most standard 
microscopic methods are important component of LF control program, which is aimed to 
reduce number of microfilaremic persons. The suitable blood collection and microscopic 
diagnosis in health settings can be effectively available to identify anyone infected, and 
subsequently, treated with antifilarial drug regimens. However, this specific objective of 
control is less important as the elimination is desired not just to interrupt transmission and 
clear human infection on a large-scale, but also to reduce the morbidity attributed to the 
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disease and hence improve both personal-focused hygiene and health care to all 
beneficiaries in target population at risk (Table 2).  
 
 Control Elimination 
1. Definition - Reduction of microfilaremia 
prevalence 
- Reduction of microfilaremia 
prevalence as arbitrarily 
qualitative or quantitative level 
of control as no longer a public 
health problem 
2. Outcome 
indicators as 
options for 
monitoring tools 
- Annual infection prevalence;  
microfilaremia rate (a 
microfilaremic number 
surveyed in endemic 
population) 
- Disease rate (a number of 
disease cases surveyed in 
endemic population) 
- Annual transmission potential 
(ATP) (i.e., a number of 
infective bite per annum which 
acquire the infection) as 
mosquito infection rate is not 
useful indicator  
- Degrees to which transmission 
is interrupted; microfilaremia 
rate mosquito infection rate 
and antigenemia rate 
- Disease rate is not useful 
indicator  
2.1 Objective - To assess whether the control 
program achieves its goals or 
desired outcomes (e.g., 
reduction in microfilaremia 
and/or disease prevalence) 
- To assess whether the 
elimination program achieves 
its goals or desired outcomes† 
(e.g., reduction in 
microfilaremia prevalence, 
antigenemia prevalence)  
3. Process indicators 
as options for 
monitoring and 
evaluation tools  
- Coverage of selective treatment 
and follow-up, as mosquito net 
utilization, insecticide spraying 
and reservoir control can be 
useful indicators 
- Mass treatment coverage, drug 
compliance coverage (e.g., 
adverse drug reactions 
prevalence and severe adverse 
event reports), KAP survey   
3.1 Objective - To assess how well the various 
components of the control 
program are functioning (e.g., 
the number of newly and 
follow-up microfilaremic 
persons treated with antifilarial 
drugs) 
- To assess how well the various 
components of the elimination 
program are functioning‡ (e.g., 
the number of new infections, 
the number of drug tablets 
distributed) 
Adapted from the GPELF (http://www.who.int/lymphatic_filariasis/disease/en/). 
†,‡Outcome indicators can be optionally used for monitoring systems; longitudinal surveillance of 
populations in sentinel sites, cross-sectional “spot checks” in other sites, and auxiliary “background” 
surveillance. 
KAP - Knowledge, attitudes and practices.  
Table 2. Rational approaches to lymphatic filariasis control and elimination  
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Tools Advantages for the applications Chief obstacles when 
applied or used in 
demonstrated areas
References 
ICT 
Filariasis 
 Simple-to-use rapid diagnostic 
test kit commercially available 
for use in qualitative detection 
of W. bancrofti adult worm 
circulating antigens present in 
whole blood/serum/plasma 
samples; stronger positive test 
line equivalent to higher 
antigen levels; 
 Sensitive and specific for 
anytime-of-day determination 
of active infection 
(antigenemic) whether 
microfilaremia is present, or 
the treatment is given; 
 Highly reproducible and 
practical when lots of large-
scale blood samples (100 l 
each) are analyzed  either 
under the field conditions by 
not-well-trained field workers 
or in laboratory settings (with 
100 l each of serum/plasma 
samples freshly prepared or 
frozen) by laboratory personnel 
in order to assess the human 
infection rates in areas known 
as endemic for W. bancrofti or 
respective areas of 
emergence/reemergence; 
 Suitable for rapid assessment 
survey to detect the early 
infection in endemic carriers 
including migrants, refugees, 
any persons who work in 
endemic areas (mine in 
rainforest and border) for 
years, or visitors to the areas; 
 Suitable to monitor and 
evaluate the infection in 
humans inhabiting in risk areas
in initial surveillance before 
MDA; drug responses during 
MDA; and the new infection in 
post-MDA areas whether they 
are certified as eliminated areas
 Costly; 
 Indicate, but not 
quantify, the level of 
the circulating 
antigens; somehow, 
provides false-
negative 
identifications with 
the infections 
harboring very low 
antigen titers; 
 Cannot differentiate 
the status between 
infection and 
disease, occurrence 
and   recurrence, or 
sensitivity and 
resistance 
 Primarily requires 
standardization and 
quality control of 
lots of samples 
(finger-prick blood) 
that are collected 
and analyzed 
Weil & Liftis, 1987 
Weil et al, 1987; 
1996; 1997 
Freedman et al, 
1997 
Ramzy et al, 1999 
Bhumiratana et al, 
1999; 2002; 2004; 
2005 
Nguyen et al, 1999 
Phantana et al, 
1999 
Simonsen et al, 
1999  
Omar et al, 2000 
Pani et al, 2000; 
2004 
Sunish et al, 2002; 
2003 
Braga et al, 2003 
Engelbrecht et al, 
2003 
Koyadun et al, 
2003 
Nuchprayoon et 
al, 2003 
Siriaut et al, 2005 
Ruberanziza et al, 
2009 
Foo et al, 2011 
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Tools Advantages for the applications Chief obstacles when 
applied or used in 
demonstrated areas
References 
Og4C3 
ELISA 
 Commercially available 
diagnostic test kit, and 
principally the same when use 
in qualitative and quantitative 
detection of active W. bancrofti 
infection, but more sensitive 
and specific than the ICT 
Filariasis;  
 Highly reproducible when lots 
of large-scale serum/plasma 
samples (100 l each of freshly 
prepared or frozen samples) 
are analyzed in the public 
health reference laboratory or 
research institutes in order to 
assess the human infection 
rates, and to monitor and 
evaluate the infection or drug 
responses in individuals or in 
the target population under the 
circumstances described above;
 Costly, labor-
intensive and 
intrusive  
 Cannot differentiate 
the status between 
infection and 
disease, occurrence 
and   recurrence, or 
sensitivity and 
resistance 
 Primarily requires 
standardization and 
quality control of 
lots of venous blood 
samples 
(subsequently 
prepared for sera or 
plasma) that are 
collected, 
transported, stored 
and analyzed; 
 Also requires well-
trained field 
workers and 
laboratory personnel 
More & Copeman, 
1990 
Turner et al, 1993 
Chanteau et al, 
1994a; 1994b 
Lammie et al, 1994 
McCarthy et al, 
1995 
Rocha et al, 1996 
Nicolas, 1997 
Ismail et al, 1998 
Eberhard, 1997 
Simonsen and 
Dunyo, 1999 
Nuchprayoon et 
al, 2003 
Bhumiratana et al, 
2004; 2005 
Polymerase 
chain 
reaction 
(PCR) 
 Very highly sensitive and 
specific for the microfilaremic 
infections with W. bancrofti and 
B. malayi in humans and 
mosquitoes distinguishable 
from other filarial nematode 
parasites such as O. volvulus, D. 
immitis, D. repens and B. 
pahangi;  
 Highly reproducible and 
practical when lots of samples 
as low as 20 l human blood, 
individual mosquito (dissected 
or whole body), or mosquito 
pool, are analyzed in the public 
health reference laboratory or 
research institutes in order to 
assess the human and 
 Too costly, labor-
intensive, intrusive, 
in-house developed 
tool 
 Primarily requires 
standardization and 
quality control of 
lots of samples 
(finger-prick or 
venous blood, or 
pooled wild-caught 
mosquitoes) that are 
collected, 
transported, stored 
and analyzed; 
 Also requires well-
trained field 
workers or 
Chanteau et al, 
1994c 
Lizotte et al, 1994 
McCarthy et al, 
1996 
Siridewa et al, 
1996 
Williams et al, 
1996 
Zhong et al, 1996 
Ramzy et al, 1997 
Nicolas et al, 1999 
Cox-singh et al, 
2000 
Thanomsub et al, 
2000 
Pradeep Kumar et 
al, 2002 
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Tools Advantages for the applications Chief obstacles when 
applied or used in 
demonstrated areas
References 
mosquito infection rates, and to 
monitor and evaluate the 
infections or drug responses in 
individuals or in the target 
population under the 
circumstances described above;
 Can differentiate the status 
between infection 
(microfilaremia) and disease, 
occurrence (new infection) and 
recurrence, or sensitivity and 
resistance; 
 Detection limit of as low as one 
Mf per blood volume tested 
(up to 1 ml), or one juvenile 
larva (L1, L2 or L3) per pooled 
mosquitoes (up to 100) 
laboratory personnel 
and accessory 
equipments for 
DNA preparation 
and analysis of PCR 
products; 
 Cannot differentiate 
larval stages (L1, L2 
or L3) in infected 
mosquitoes 
Fischer et al, 2003 
Kanjanavas et al, 
2005 
Nuchprayoon et 
al, 2005; 2007 
Rao et al, 2006 
Mishra et al, 2007 
WHO, 2009 
Bhumiratana et al, 
2010 
Pechgit et al, 2011 
Takagi et al, 2011 
Table 3. Direct determination tools for use as part of the Global Program to Eliminate 
Lymphatic Filariasis 
To meet this objective, a large-scale transmission control requires a current magnitude and 
geographical distribution of the disease in the at-risk population. To understand the extent 
to which the target population needs to be designed for MDA and monitored whether the 
MDA implementation is effective, such surveillance and monitoring systems are required. 
To identify the communities with, or at risk of, the infection, for instance, the direct 
assessment techniques (Table 3) are required for practical use both in initial surveillance for 
filarial infection and in monitoring and evaluating the effectiveness of mass treatment, as 
part of the GPELF (WHO, 1999a; 1999b; Ottesen, 2000). In this regard, the mass treatment 
with more effective antifilarial drug regimens as well as the availability of other existing and 
alleviating control measures has been deliberately implemented to meet such these highly 
achievable objectives of the elimination. Nonetheless, in addition to what is recommended 
by WHO, the GPELF requires for ground-breaking development of systems, protocols and 
tools that will be able to be convincingly applied to or routinely used in the PELF to fix 
undesirable events of mass treatment impacts in different complex epidemiological settings 
(Kyelem et al, 2008; Ottesen et al, 2008; WHO, 2008; 2010).  
3. Parasite infection and drug responsiveness 
3.1 Microfilaremia and drug-responsive microfilaremia 
In an endemic population that represents the infection and disease dynamics in nature, the 
asymptomatic microfilaremia is a stage of the active infection with filarial adult worms 
(Srividya et al, 1991; Meyrowitsch et al, 1995), which regulate host immune responses 
(hypoimmune responsiveness) in infected individuals (Bundy et al, 1991; Grenfell et al, 1991; 
Maizels and Lawrence, 1991; Mitchell, 1991; Grenfell and Micheal, 1992; Ottesen, 1992; 
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Simonsen et al, 1996; 2008; Ravindran et al, 2003). This phenomenon results in 
immunotolerance, i.e., a prolonged induction of the balance of immune defense to the 
parasites stimulated by the adult worms, in most asymptomatic microfilaremic persons. The 
female adult worm involves in regulation of the host microfilaremia. The fecundicity (a 
period of pregnancy) allows its fertilization to produce a diverse number of the offspring 
microfilariae. Although the proportion of microfilariae can be removed from the blood 
circulation in patients, there are the plenty of microfilariae, which circulate in the peripheral 
blood and show the appearance both nocturnally and diurnally. This microfilarial 
periodicity or circadian cycle of the parasite in humans is clinically unimportant for 
treatment but very important for its epidemiologic implication, which plays a significant 
role in diagnosis, surveillance and epidemiology. The parasite infection is the foundation for 
the processes that not only determine the infection prevalence but also monitor and evaluate 
the effectiveness of the treatment with the antifilarial drugs in infected individuals. In this 
regard, the amount of microfilaremia seems to be a function of naturally-acquired infection 
loads, which refers to as the most viable microfilariae, and drug-responsive microfilaremia 
refers to as the affected parasite population that harbors a diverse range of viable and non-
viable microfilariae (Pechgit et al, 2011). These outcome indicators are useful for monitoring 
and evaluating the benzimidazole susceptibility of the filarial nematode parasites in the 
population in areas of the PELF implementing the MDA 2-drug regimen either albendazole 
plus DEC or albendazole plus ivermectin.  
However, the MDA 2-drug regimen is not the only factor that shapes the parasite 
population under complex epidemiological settings. Of note, the W. bancrofti populations 
have ability to provoke the genetic variability that shows the important implications in the 
endemic populations targeted by the MDA (Pradeep Kumar, 2000). The existence of genetic 
diversity of W. bancrofti populations that has greater heterogeneity under DEC therapy and 
vector control gives rise to questioning about the development of drug resistance in LF, 
which possibly occurs in the target populations. The selection pressure is an intensity of 
selection affecting the frequency of genes in a parasite population. The selection that 
increases or decreases the susceptibility of the parasite population depends on the frequency 
of the alleles involved. The genetic polymorphism occurring in the W. bancrofti population 
under the selection pressure(s) may evoke gradually under specified conditions to yield the 
fitness, which can be determined by a genotype in the parasite population. The increase in 
the parasite fitness can be estimated by the equilibrium frequencies of the alleles (genotypes) 
at heterozygote advantage in a hypothethical population. That is, rapid establishment of 
advantageous alleles in the W. bancrofti population, called “selection sweep”, may evoke 
with advantageous drug-resistant genotypes epidemiologically linked to other factors 
shaped by the host and environment (Schwab et al, 2006: 2007; Churcher et al, 2008). 
Eventually, it may reduce the genetic variation in the population. 
3.2 Benzimidazole-susceptibility of the parasite 
This chapter emphasizes microfilaremia responsiveness in the population under the 
suppression of the PELF implementing MDA 2-drug regimen, 6 mg/kg DEC plus 400 mg 
albendazole. The microfilaremia responses against the DEC are the foundations of 
understanding how the albendazole exerts the effects on the parasite population in addition 
to what is observed by DEC alone. The DEC is known as the oldest of the antifilarial drugs 
used in the LF control. The single-dose drug acts as microfilaricide as does the effective 
ivermectin (de Silva et al, 1997; Ottesen, 2000; Molynuex et al, 2003; Ottesen et al, 2008) 
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while its macrofilaricidal activity is not definitely effective against adult worms (Eberhard et 
al, 1991; Norões et al, 1997; Dreyer et al, 1998; Rajendran et al, 2002; 2004; Oliveira-Menezes 
et al, 2007). The adult worm loads that are age-dependent (Lammie et al, 1994; Rajendran et 
al, 2002) are susceptible to treatment with the DEC alone or even combination with 
albendazole (Norões et al, 1997; Rajendran et al, 2002). It was seen that DEC alone disturbs 
the microfilarial sheath of some filarial species while it has effects on the oogenesis and 
fertilization of female adult worms. Nonetheless, little is known about the filarial nematode 
parasites whether they evoke resistance mechanism against DEC due to the lack of 
deepening its mechanism of action, particularly the availability in parasite tissues and the 
selectivity on parasite targets. Oliveira-Menezes et al (2007) demonstrated that DEC has 
minor effects on alterations of the cuticle or surface of both male and female adult worms; 
these responsible parasites were collected from the W. bancrofti-infected patients treated 
with DEC, as compared to those isolated from the untreated patients. Additionally, such 
alterations are seen in adult worms recovered from the patients treated with DEC plus 
albendazole. The possible explanation is that the potential adulticidal effect of albendazole 
relative to what is observed by the DEC alone. The subtle alterations imply the distinct 
morphologic characteristics of the parasite itself or the complex host-parasite interactions, 
and if implemented and continuously prolonged, the annual mass treatment with DEC plus 
albendazole has not yet become an apparent issue, particularly the impacts on the parasite 
population adaptation. Of note, the O. volvulus parasite develops the mechanism involved in 
resistance to ivermectin (Awadzi et al, 2004). Do the filarial nematode parasites have 
mimicry in the resistance mechanisms to ivermectin and albendazole? However, detailed 
study of the parasite resistance to albendazole has not been established.  
Focus is on the MDA 2-drug that acts as effective microfilaricide while its aberrant activity 
that influences microfilaremia response to its efficacy in microfilaricidal activity. Provided 
this phenomenon occurs, the expected outcomes of such drug failure will impact on solving 
the solutions and paving the implications of how they will adapt under the certain 
circumstances and how we will also mitigate their adaptation. Most studies enlightened the 
understanding of this effective deworming MDA 2-drug, which plays the significance of 
reduction of the infection prevalence. A single-dose combined treatment with DEC plus 
albendazole has short- and long-term effects on W. bancrofti microfilaremics in the endemic 
populations (Ismail et al, 1998; Ottesen et al, 1999; El Setouhy et al, 2004; Rajendran et al, 
2004). Compared to those receiving DEC alone, an additional benefit of the combined drugs 
results in decline in annual cyclic infection prevalence due to progressive reduction in 
density of W. bancrofti microfilaremia. Although its macrofilaricidal effect on clearance of 
W. bancrofti antigenemia has been reported (McCarthy et al, 1995; Eberhard, 1997; 
Rajendran et al, 2002; 2004; Koyadun et al, 2003; Bhumiratana et al, 2004; Siriaut et al, 
2005; Bhumiratana et al, 2005; Yongyuth et al, 2006), the DEC alone or co-administered 
with the albendazole does not clear rapidly the antigenemia. The MDA with the DEC 
alone will recover an increase in the antigenemia prevalence of W. bancrofti unless there is 
yearly-round MDA in the population (Rajendran et al, 2002). A 400 mg single oral-dose 
albendazole regimen is broad-spectrum effective against helminthiases (Albonico, 1994; 
de Silva et al, 1997; Beach et al, 1999; Ottesen et al, 1999; Horton, 2000) and, as co-
administered orally with DEC, a synergistic and long-term effect on geohelminths has 
been proven useful for ‘beyond-lymphatic filariasis’ elimination program (Ottesen et al, 
1997; 1999; Ismail et al, 1998; Horton et al, 2000; Ottesen, 2000; Mani et al, 2002; 2004; 
Molynuex et al, 2003; Yongyuth et al, 2006).  
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Few reports established the evidence that the human filarial nematode parasites provoke 
molecular mechanism involved in benzimidazole sensitivity/resistance until recently 
findings of the genetically-induced resistance against benzimidazole compounds have been 
well documented in veterinary nematode parasites (Beech et al, 1994; Kwa et al, 1995; 
Humbert et al, 2001; Bennett et al, 2002; Drogemuller et al, 2004; Robinson et al, 2004; Cole et 
al, 2006; Ghisi et al, 2007). Resistance to albendazole in veterinary nematodes is known to be 
caused by either one of two single amino acid substitutions from phenylalanine to tyrosine 
in parasite -tubulin at position 167 or 200. The genetically stable W. bancrofti -tubulin gene 
responsible for a molecular mechanism of drug resistance has been proposed as that of the 
veterinary helminth parasites is performed under selection of albendazole and ivermectin. 
The W. bancrofti population isolated from the patients treated with a combination of 
albendazole and ivermectin had significantly higher genotypic frequencies associated with 
resistance at position 200 (Schwab et al, 2005). A resistance mutation was not detected at 
position 167. Hoti et al (2003, 2009) reported that the polymorphism in the codon of this 
residue in W. bancrofti populations representing geographically distant areas of India, 
through sequencing exon 5 region of -tubulin isotype 1 gene. The nucleotide sequence data 
showed that W. bancrofti isolates from wide geographic areas of India had codon for Phe 
(TTC) at position 200, suggesting that the parasite might be genetically sensitive to 
benzimidazole. Similarly, Bhumiratana et al (2010) and Petchgit et al (2011) demonstrated 
that the W. bancrofti population recovered from the dynamic cross-border migrant 
population from areas that have been targeted by the MDA 2-drug regimen (300 mg DEC 
plus 400 mg albendazole) elicits the genetic background of benzimidazole susceptibility; a 
resistance mutation has not been observed at position 167 or 200. However, the albendazole, 
anthelmintic benzimidazole, is being co-administered with an antifilarial drug such as DEC, 
part of the PELF implementing in many endemic countries. But this drug is known to result 
in the faster development of drug resistance in the veterinary nematode parasites and hence 
it is necessary to monitor drug sensitivity among the responsible W. bancrofti populations.   
4. Molecular diagnosis and monitoring of benzimidazole susceptibility 
4.1 Parasite beta-tubulin encoding gene as molecular marker 
Molecular mechanisms of benzimidazole resistance in nematode parasites are hypothesized. 
However, detailed study of benzimidazole resistance in trichostrongylids found that the -
tubulin encoding gene involved in benzimidazole susceptibility is responsible for the 
genetic inheritance of resistance in the veterinary nematode parasites under selection with 
benzimidazole that involves one of two single amino acid substitutions from phenylalanine 
(Phe) to tyrosine (Tyr) in parasite -tubulin at position 167 or 200 (Beech et al, 1994; Kwa et 
al, 1993; 1994; 1995; Roos et al, 1990; Elard et al, 1996; Elard and Humbert, 1999; Humbert et 
al, 2001; von Samson-Himmelstjerna et al, 2002; Winterrowd et al, 2003; Drogemuller et al, 
2004; Cole et al, 2006; Ghisi et al, 2007). The potential point mutation occurs at the DNA 
level by nucleotide substitution for the codon for amino acid position 200 of the -tubulin 
gene, a substitution of TTC (Phe) with TAC (Tyr). This irreversible change brings about 
distinguishment of the responsible parasite population between benzimidazole-sensitive 
and -resistant nematodes. This principal mechanism for benzimidazole resistance is 
postulate to involve changes in the selectivity of the benzimidazoles on the primary 
structure of β-tubulin molecules, a building block of the microtubule in the parasites (Lacey, 
1988; Lacey and Gill, 1994; Robinson et al, 2004). 
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Fig. 3. ClustalW alignment of the filarial β-tubulin gene. The partial nucleotide sequence 
representatives (accession no. and positions): Brugia malayi (BRQD553TR, 3-789), Brugia 
pahangi (M36380, 2267-3054), Wuchereria bancrofti (AY705383, 109-916), Onchocerca volvulus 
(AF019886, 1582-2400) and Dirofilaria immitis (HM596854, 1462-2244) are shown as coding 
(upper case) and non-coding (lower case) sequences. The deduced amino acid sequences for 
the conserved domains are shown for all taxa aligned; D. immitis and O. volvulus have one 
amino acid substituted at position Ala218Thr. The gap is performed on the maximum 
homology (insertion/deletion), which represents conserved () and degenerate nucleotide 
residues and the regions designed to amplify specifically the target sequences based on the 
Wbtubb primer sets (light-gray boxes), both forward () and reverse (). Hypothetically, 
two amino acid substitutions at positions Phe167Tyr and Phe200Tyr (dark-gray boxes) 
retained in DNA fragments (141 and 174 bp) could be identified using the PCR detection 
system described by Bhumiratana et al (2010) and Pechgit et al (2011).  
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Intriguingly, such mimicry in molecular mechanism for benzimidazole resistance in the 
filarial nematode parasites has been increasingly investigated, based basically on the 
molecular characterization of the homologous -tubulin gene retained in their genome and 
the advantageous fitness of benzimidazole-resistant genotypes in the population (Roos et al, 
1995; Elard et al, 1998; Elard et al, 1999; Silvestre et al, 2001; Silvestre and Humbert, 2002).   
The nematode parasites possess the single-copy homologous -tubulin (tubb) gene that 
encodes a -tubulin polypeptide, 448 amino acids (Met1 to Glu448). Hypothetically similar 
to that of trichostrongylids, the binding of benzimidazoles to conserved domains (of the 
exons 4 to 6) leads to blocking an assembly of tubulin (TUBB), and thus disrupting 
structural formation of microtubule (cytoskeleton protein) in the nematode parasites. The 
nucleotide sequences of the homologous -tubulin gene as molecular marker and other 
related TUBB gene family of the nematode parasites can be retrieved from the genome 
databases: the GenBank at the National Center for Biotechnology Information (NCBI),  
http://www.ncbi.nlm.nih.gov/genbank/, the European Molecular Biology Laboratory 
(EMBL) http://www.ebi.ac.uk/, and the DNA DataBank of Japan (DDBJ) 
http://www.ddbj.nig.ac.jp/. The website of nematode and neglected genomics 
(http://www.nematodes.org/fgn/index.html) establishes genome database, especially for 
the filarial genome project (FGP), which includes published complete B. malayi genome. 
Meanwhile, the homologous sequences of B. malayi -tubulin gene can be obtained from the 
TIGR genome database (http://www.tigr.org/tdb/e2k1/bma1).  
The structural organization of homologous tubb genes of two filarial nematode parasites, 
B. pahangi (Guenette et al, 1991) and D. immitis (Bourguinat et al, 2011), has been shown 
for the establishment of complete coding sequences that span 9 discrete exons: exon 1 
(Met1 to Lys19), exon 2 (Phe20 to Asp55), exon 3 (Gly56 to Gln131), exon 4 (Gly132 to 
Lys174), exon 5 (Val175 to Leu228), exon 6 (Val229 to Gln292), exon 7 (Met293 to Arg324), 
exon 8 (Glu325 to Thr386) and exon 9 (Ala387 to Glu448). The homology is 78% at DNA 
level due to bias of codon usage and insertion/deletion of intron sequences (Fig. 3). 
Among these, the exons 4 and 5 confer hypothetical point mutation at amino acid 
positions Phe167Tyr (or TTT/TAT) and Phe200Tyr (or TTC/TAC), based only on the 
second nucleotide base changed in the codons. In the homologous segment of its closely 
related taxa, W. bancrofti -tubulin (Wbtubb) gene that possesses two distinct exons, 4 
(Gly132 to Lys174) and 5 (Val175 to Leu228), with flanking intron sequences (Fig. 3) 
shares the homology at DNA level with B. malayi and B. pahangi (93% similarity), 
compared to O. volvulus and D. immitis (76% similarity) (Bhumiratana et al, 2010; Pechgit 
et al, 2011). This target DNA has been proved useful for designing Wbtubb locus-specific 
primers to discriminate between Wbtubb and other homologs of human and animal 
filariids. Based on its usefulness in molecular diagnosis and monitoring of the infection 
carrying the benzimidazole-sensitive or resistant phenotypes, the PCR applications of this 
molecular marker for W. bancrofti have been well documented (Hoti et al, 2003; 2009; 
Schwab et al, 2005; Bhumiratana et al, 2010; Pechgit et al, 2011).  
4.2 Polymerase chain reaction-based approaches 
In contrary to the antigen detection methods such as ICT Filariasis and Og4C3 ELISA that 
provide the proof of W. bancrofti antigenemic infection in human blood, the microfilarial 
DNA detection by PCR provides the evidence of W. bancrofti microfilaremic infection in 
human blood and mosquito (Table 3). As a result of the existence of genetically stable  
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Fig. 4. A purposed scheme for PCR detection of W. bancrofti benzimidazole-susceptible 
isolates in human blood and mosquito.  
 
Primer 
Name 
Sequence 
(5’ to 3’) 
Direction
Length
(bases)
Expected 
amplicon 
size (bp)
Hypothetical 
nucleotide 
positions 
Susceptible(S)/ 
resistant(R) 
genotypes 
investigated
Reference 
BT9 
CAGGTACAGATT
GCTACAGT
Forward 20 607c 
(TTT)167(TAT)
(TTC)200(TAC)
S/Phe167 
S/Phe200 
Bhumiratana 
BT12 
GCGATTTAAACC
CGACAGC
Reverse 19  et al (2010) 
BT121a 
GGATCCGTATCA
GATGTTGTG
Forward 21 174d 
(TTC)200(TAC) S/Phe200 
Bhumiratana 
BT122b 
GAATTCCAAGTG
GTTGAGGTCG
Reverse 22  et al (2010) 
Wt2F 
GTATCAGATGTT
GTGTTG
Forward 18 475e 
(TTC)200(TAC) S/Phe200 
Hoti et al 
Wt2R 
ACGACTTGAATG
AGTTGTC
Reverse 19  (2003) 
Wbbt2
F 
TATCAGATGTTG
TGTTGG
Forward 18 475f 
(TTC)200(TAC) S/Phe200 
Hoti et al 
Wbbt2
R 
CTGTTGAG 
AAGTTCAGCA
Reverse 19  (2009) 
5’modifications with additional recognition sequences: aBamH I (GGATCC) and bEcoR I (GAATTC). 
c dRetrieved Wuchereria bancrofti genome accession nos.: AY705383 and GU19071824. 
eRetrieved Brugia pahangi genome accession nos.: M36380.  
fRetrieved Wuchereria bancrofti genome accession nos.: EF190199-190209, EF492870-492878. 
Table 4. The β-tubulin isotype 1 gene-specific primers used in the PCR amplification of W. 
bancrofti benzimidazole-susceptible isolates  
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W. bancrofti –tubulin gene, the nested PCR amplification can work well with the 
microfilaremic infection that responds to treatment with MDA 2-drug regimen (DEC plus 
albendaozle) (Pechgit et al, 2011). This newly developed PCR assay in addition to promising 
advanced tool (Hoti et al, 2003; 2009; Bhumiratana et al, 2010) has the potential benefits in 
the molecular diagnosis and monitoring of the infection, as compared to the other PCR 
amplification methods previously described elsewhere (Table 3). The concepts for PCR 
assays based on the Wbtubb locus-specific primers (Table 4) have been proposed in two 
applicable formats: the locus-specific nested PCR and allele-specific nested PCR. These 
applications have established the advantages on how to circumvent some common 
counterintuitive problems of conventional PCR with regards to both parasite genome 
analysis and low-copy gene detection; such detailed study has been well established by 
Pechgit et al (2011). The W. bancrofti microfilarial DNA detection methods depends much on 
the purity and quantity of the microfilariae recovered from different blood sample 
preparations. The purified aggregate parasite number in the absence of human host white 
blood cells, for example, are ideal for the quality of DNA extract, which serves as target 
sequences in the PCR reactions. In general, most PCR methods for the detection of W. 
bancrofti distinguishable from other filarial nematode parasites in human and mosquito is 
based on the repetitive Ssp I sequences, which are highly copy number per haploid genome. 
However, PCR amplification based on this Ssp I locus provides the positive identifications of 
the parasite infection existed in specimens of choice. The assay does not determine the 
infection that responds to benzimidazole sensitivity/resistance; such responsible W. 
bancrofti parasite population is amplified based on the –tubulin gene which is single copy in 
haploid genome. Therefore, the amplification is performed using the Wbtubb locus-specific 
nested PCR and allele-specific nested PCR that provides the proof of the W. bancrofti 
infection carrying benzimidazole-sensitive/resistant phenotypes; methodologically, the 
technical requirements for their applications have been described by Pechgit et al (2011) and 
Hoti et al (2009). More specific, based on our experience, the Wbtubb locus-specific nested 
PCR with thermocycling modifications using touchdown and touchup cycles has been 
applied or used in detection and characterization of W. bancrofti infection both in human 
blood from patients untreated or treated with DEC plus albendazole and in wild-caught 
mosquito, provided such infections carrying benzimidazole-sensitive/resistant strains are the 
same source of the parasite population (Fig. 4). Hypothesis is that whether the parasite 
infection is genetically predisposed to the MDA 2drug regimen (DEC plus albendazole) in 
areas under suppression of PELF, it will have frequencies of benzimidazole-susceptible 
homozygous allele (SS) greater than benzimidazole-susceptible heterozygous allele (Sr) and 
homozygous resistant allele (rr), which are associated with albendazole resistance, unless the 
parasite fitness is increased. This also permit the monitoring and evaluation of the parasite 
fitness to better understand theoretically and hypothetically evolutionary biology and ecology 
of the parasite, by which the human hosts play a key as a major source of selective pressures 
on the adaptation of parasite population constrained by environmental conditions.       
5. Future perspectives 
The GPELF has been deployed into the endemic countries implementing MDA 2-drug 
regimes (i.e., single annual doses of albendazole in combination with DEC or ivermectin) to 
reduce microfilaremia prevalence to levels low enough (principally lower than transmission 
threshold) to interrupt transmission of the disease in the absence of vector control. Based on 
scientific information on drug resistance to anthelmintics, the issue of albendazole resistance 
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in the W. bancrofti parasite has assumed increasing importance since the GPELF is 
implemented on a large-scale in at-risk populations in different complex epidemiological 
settings, and predictably, the implementation phrase of the program will increase. Many 
studies have shown some vulnerability in how the parasite has the ability to evoke molecular 
mechanisms for resistance to anthelminthics as the nematodes of veterinary importance have 
developed resistance against both albendazole and ivermectin. Furthermore, there have been 
lines of evidence that the vulnerability of helminthiasis control programs that employ the 
MDA with these drugs is associated with several factors that facilitate the promotion of drug-
resistant strains. At the same time, the factors are considered concerning the new options of 
drug combinations with different parasite targets or modes of actions to keep active shelf-life 
of DEC because the filarial nematode parasites have long life-span and complex life-cycle 
development. Likewise, to better understand what is relative to achieve MDA’s goal to 
confront growing trend of drug resistance, it is essential for the development of molecularly 
diagnosing and monitoring the benzimidazole sensitivity/resistance in areas of long-running 
PELF program implementation using albendazole plus DEC or albendazole plus ivermectin. 
More applicable tools which will be validated in effective manner are also required to explore 
the genetic basis for resistance to anthelminthics. 
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